| Name | Title | Contact Details |
|---|---|---|
Megan Barbour |
Chief Operating Officer | Profile |
Two things distinguish CHIA in our pursuit of improving the Massachusetts health care system: our public-interest perspective, and our unique data sets. Our perspective is rooted in our independence – our agenda and findings are not colored by the special interests of industry or politics – and in the talents and commitment of CHIA employees. CHIA`s mission is to be the agency of record for Massachusetts health care information, to responsibly steward sensitive and confidential data, and to objectively report reliable and meaningful information about the quality, affordability, utilization, access, and outcomes of the Massachusetts health care system. We pursue this mission in the public interest. This informs our objective perspective, and our commitment to serving a broad, diverse audience. We are a hub, connecting our products to policymakers, public and private payers and providers, employers, researchers, and the residents of Massachusetts. Our vision is a transparent health care system where reliable information provides common ground for improvement and empowers people and organizations to make informed decisions.
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.
Healthcare Data Experts is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RAAS BLOOD PRODUCTS CO., LTD. is a Agoura Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Whatcom Health Information Network is a Bellingham, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.